Anika Therapeutics | ANIK - Betriebsaufwand

Aktienkurs
14.27
Täglich Wechseln
0.42 3.03%
Monatlich
31.52%
Jährlich
-7.88%
Q1 Prognose
13.43




Betriebsaufwand Veränderung Datum
Abbott USD 9.21B 17M 2025-12
Agenus USD 19.81M 293.94M 2025-12
Agios Pharmaceuticals USD 141.54M 11.8M 2025-12
Anika Therapeutics USD 29.97M 116.84M 2025-12
Arrowhead Research USD 223.22M 10.86M 2025-12
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Halozyme Therapeutics USD 211.07M 74.73M 2025-12
Heron Therapeutics USD 40.55M 1.46M 2025-12
Insmed USD 513.55M 109.86M 2025-12
Integra LifeSciences USD 368.92M 668.65M 2025-12
Intrexon USD 61.56M 26.1M 2024-06
J&J USD 18.97B 2.38B 2025-12
Karyopharm Therapeutics USD 61.82M 3.24M 2024-12
Ligand Pharmaceuticals USD 8.29M 32.17M 2025-09
MacroGenics USD 53.32M 13.68M 2025-12
Merit Medical Systems USD 339.74M 1.8M 2025-12
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 10.51B 1.21B 2025-12
Smith & Nephew USD 2.52B 84M 2025-12
Stryker USD 5.2B 505M 2025-12
Surmodics USD -245.35M 363.49M 2024-09
Veracyte USD 116M 7.24M 2025-12
Xencor USD 81.86M 13.35M 2025-12
Zimmer Biomet Holdings USD 1.94B 277.8M 2025-12